Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ergoferon for COVID-19 Prevention During Vaccination
NCT05069649Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of Ergoferon in coronavirus disease 2019 (COVID-19), sponsored by Materia Medica Holding. Started Oct 2021; status: completed.
02
Drugs
Ergoferon
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05069649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069649.